pyrazines has been researched along with Pulmonary Hypertension in 94 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (6.38) | 18.7374 |
| 1990's | 13 (13.83) | 18.2507 |
| 2000's | 2 (2.13) | 29.6817 |
| 2010's | 55 (58.51) | 24.3611 |
| 2020's | 18 (19.15) | 2.80 |
| Authors | Studies |
|---|---|
| Channick, R; Chin, KM; Coghlan, JG; Gaine, S; Galiè, N; Hoeper, MM; Hsu Schmitz, SF; Lang, IM; Lassen, C; McLaughlin, VV; Rubin, LJ; Sitbon, O; Tapson, VF | 1 |
| Channick, R; Chin, KM; Du Roure, C; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Jenner, B; Lang, IM; McLaughlin, VV; Rosenkranz, S; Rubin, LJ; Sitbon, O; Tapson, V | 1 |
| Maeder, MT | 1 |
| Abe, K; Ako, J; Ikeda, Y; Joho, S; Kinoshita, H; Maki, H; Matoba, S; Motoki, H; Ogo, T; Saeki, T; Sakao, S; Shimokawahara, H; Shiota, N; Sugano, T; Takama, N; Tanabe, N; Tanaka, S; Tatsumi, K; Tsujino, I; Yamamoto, C; Yoshioka, K | 1 |
| Chen, M; Chen, R; Hong, C; Lai, Y; Liu, H; Lu, J; Wang, D; Zhang, Y; Zheng, Z; Zhong, Y | 1 |
| Akashi, K; Arinobu, Y; Ayano, M; Fukata, M; Higashioka, K; Horiuchi, T; Imabayashi, K; Kashiwado, Y; Kawano, S; Kimoto, Y; Mitoma, H; Niiro, H; Ono, N; Saiki, C; Yokoyama, T | 1 |
| Bai, YZ; Cao, YQ; Dong, WP; Dong, Z; Liu, Y; Ma, XM; Wang, XW; Yang, B; Yang, DP; Yang, YC; Zeng, YY | 1 |
| Ghofrani, HA | 1 |
| Liang, L; Ma, G; Wang, D; Xu, L; Xu, X | 1 |
| Chouvarine, P; Diedrich, N; Diekmann, F; Hansmann, G; Hasan, H; Koestenberger, M | 1 |
| Blanco, I; Cruz Utrilla, A; Del Pozo, R; Escribano-Subías, P; López-Meseguer, M | 1 |
| Chen, Y; He, W; Hong, C; Liu, C; Lu, W; Ouyang, H; Wang, J; Wang, T; Yang, K | 1 |
| Black, SM; Chen, J; Chen, X; Chen, Y; Desai, AA; Duan, X; Garcia, JGN; He, W; Hong, C; Hou, C; Kuang, M; Li, M; Liao, J; Liu, C; Liu, S; Lu, W; Makino, A; Rischard, F; Tang, H; Vanderpool, RR; Wang, J; Wu, X; Yang, K; Yuan, JX; Zhang, J; Zhang, N; Zhang, Z; Zheng, Q; Zhong, N; Zou, G | 1 |
| Chan, KC; Das, BB; Jadotte, MM | 1 |
| DeChristopher, A; Fann, J; Feldman, J; Irandost, M; Radosevich, JJ | 1 |
| Boutou, A; Panagiotidou, E; Pitsiou, G | 1 |
| Adachi, S; Kondo, T; Nakano, Y | 1 |
| Benza, RL; Raina, A; Verlinden, NJ; Walter, C | 1 |
| Lafuente-Romero, A; Rodriguez Ogando, A | 1 |
| Del Pozo, R; Escribano-Subias, P; Hernandez Gonzalez, I | 1 |
| Anzai, T; Fukuda, K; Hashimoto, A; Hatano, M; Ikeda, S; Inoue, T; Ito, H; Kajinami, K; Kihara, Y; Kinoshita, H; Kuwahara, K; Murohara, T; Nakayama, T; Okazaki, O; Sakai, S; Sasayama, S; Satoh, T; Tahara, N; Takeda, Y; Takeishi, Y; Tanabe, N; Taniguchi, M; Watanabe, H; Yamamoto, T; Yamauchi-Takihara, K; Yoshioka, K | 1 |
| Clozel, M; Gatfield, J; Gnerre, C; Hess, P; Iglarz, M; Menyhart, K; Monnier, L; Morrison, K; Nayler, O; Wanner, D | 1 |
| Baker, WL; Darsaklis, K; Salerno, EL; Singhvi, A | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Remenova, T | 1 |
| Bates, RE; Frantz, RP; Thurber, KM; Williams, BM | 1 |
| Honorato Pérez, J | 1 |
| Kido, K; Macaulay, TE; Noel, ZR | 1 |
| Bruderer, S; Dingemanse, J; Hurst, N; Krause, A; Lott, D; Machacek, M | 1 |
| Alejos, J; Drogalis-Kim, DE; Gallotti, R; Satou, G | 1 |
| Hansmann, G; Koestenberger, M | 1 |
| Channick, R; Chin, K; Coghlan, G; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Grimm, D; Infanger, M; Kruger, M; Nassef, MZ; Simonsen, U; Sorensen, LM; Wehland, M | 1 |
| Dutt, M; Feldman, J; Habib, N; Radosevich, J | 1 |
| El Yafawi, R; Wirth, JA | 1 |
| Channick, RN; Chin, K; Di Scala, L; Farber, HW; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Preston, IR; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Channick, R; Chin, K; Coghlan, JG; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Greene, RA | 1 |
| Noel, ZR | 1 |
| Huang, LJ; Miu, CL; Wang, WT; Wu, CY; Zhang, CC; Zhao, MP; Zheng, MX | 1 |
| Ecker-Schlipf, B | 1 |
| Fanous, SM; Janmohamed, M | 1 |
| Ais, A; Beaudet, A; Gil, A; Jiménez, A | 1 |
| Beghetti, M; Channick, RN; Chin, KM; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, VV; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Escribano Subías, P; Lázaro Salvador, M; Rodriguez Padial, L | 1 |
| Eba, S; Hoshikawa, Y; Ishida, K; Kondo, T; Mitsuishi, Y; Moriguchi, T; Okada, Y; Satoh, H; Shimizu, T; Shimokawa, H; Watanabe, T; Yamamoto, M | 1 |
| Lin, M; Luan, Y; Ma, Y; Wang, YB; Wang, YY; Zhang, X; Zhang, ZH; Zhu, XB | 1 |
| Lin, M; Luan, Y; Ma, Y; Wang, YB; Wang, ZS; Zhang, X; Zhang, ZH; Zhu, XB | 1 |
| Lang, IM; Skoro-Sajer, N | 1 |
| Fujimoto, T; Koyama, A; Kurihara, T; Nishikawa, A; Okamoto, Y; Shiotani, C; Tamura, S | 1 |
| Feng, EZ; Huang, NX; Tian, ZX; Yang, SY; Yin, H; Zhang, Y | 1 |
| Asaki, T; Clozel, M; Gatfield, J; Hamamoto, T; Kuwano, K; Morrison, K | 1 |
| Sharma, K | 1 |
| Adzerikho, I; Channick, R; Chin, KM; Di Scala, L; Frey, A; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; Liu, J; McLaughlin, VV; Moiseeva, O; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, V; Zeng, X | 1 |
| Amar, D; Boucly, A; Chaumais, MC; Humbert, M; Jaïs, X; Montani, D; O'Connell, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Scott, LJ | 1 |
| Channick, RN; Tamura, Y | 1 |
| Chen, J; Raj, JU; Ramchandran, R; Sun, M; Yang, Q | 1 |
| Gall, H; Ghofrani, HA; Grimminger, F; Grimminger, J; Richter, MJ | 1 |
| Horn, EM; Krishnan, U | 1 |
| Adams, H; Prior, DL; Williams, TJ | 1 |
| Ball, S; Bandyopadhyay, D; Das, A; Ghosh, RK; Gupta, A; Mondal, S; Saha, D | 1 |
| Farber, HW; Moll, M; Sardana, M | 1 |
| Chin, KM; Hardin, EA | 1 |
| Allanore, Y; Bruni, C; Distler, O; Gabrielli, A; Iannone, F; Matucci-Cerinic, M; Praino, E | 1 |
| Kaluski, E; Mishra, A; Singh, M | 1 |
| Burness, CB; Duggan, ST; Keam, SJ | 1 |
| Hashino, A; Kosugi, K; Kuwabara, K; Kuwano, K; Noda, K | 1 |
| Bonderman, D; Degano, B; Delcroix, M; Efficace, M; Galiè, N; Giorgino, R; Hoeper, MM; Karlócai, K; Kurzyna, M; Lang, IM; Simonneau, G; Torbicki, A | 1 |
| Huh, JW; Kim, HJ; Kim, SY; Lee, JH; Lee, SD; Lee, YS; Oh, YM; Park, MK; Ro, JY | 1 |
| Clozel, M; Ernst, R; Haag, F; Kauser, K; Morrison, K; Studer, R | 1 |
| Kovacs, G; Olschewski, H | 1 |
| Morrell, N; Sitbon, O | 1 |
| Li, J; Zhou, DB | 1 |
| Chen, DZ; Huang, RJ; Liao, CX | 1 |
| Cao, W; Luo, W; Zeng, Z | 1 |
| Liu, SM; Tang, TQ | 1 |
| Cao, W; Guo, Z; Luo, W | 1 |
| Arnal, F; Hill, NS; Klinger, JR; Petit, RD; Warburton, RR; Wrenn, DS | 1 |
| Liu, B; Liu, J; Wu, K; Xu, Z; Yan, Y | 1 |
| Chui, S; Ding, W; Wang, B; Yang, B; Zhou, C | 1 |
| Cui, S; Ding, W; Wang, B; Yang, B; Zhou, C | 1 |
| Chen, X; Sun, R; Yan, Y | 1 |
| Jeffery, TK; Wanstall, JC | 1 |
| Abbott, BM; Barthlow, HG; Bialecki, RA; Caccese, RG; Fisher, CS; Rumsey, J; Rumsey, W; Stow, RB | 1 |
| Chen, D; Huang, R; Liao, C | 1 |
| Barer, G; Bee, D; Emery, C; Oddoy, A | 1 |
| Chen, BH | 1 |
| Barer, GR; Cai, YN | 1 |
| Duan, SF; Peng, W | 1 |
| Yuan, XJ | 1 |
| Sun, RY | 1 |
| Cui, XX; Tang, TQ; Zhou, HX | 1 |
| Wang, DX; Wu, F; Zou, AP | 1 |
25 review(s) available for pyrazines and Pulmonary Hypertension
| Article | Year |
|---|---|
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2022 |
An evaluation of selexipag for the treatment of pulmonary hypertension.
Topics: Acetamides; Administration, Oral; Adult; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2017 |
Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
Topics: Acetamides; Costs and Cost Analysis; Hospitalization; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines | 2017 |
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Adult; Animals; Antihypertensive Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Topics: Acetamides; Acetates; Administration, Oral; Animals; Antihypertensive Agents; Drug Design; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2017 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Hospitalization; Humans; Hypertension, Pulmonary; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Topics: Acetamides; Animals; Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; Prodrugs; Pyrazines; Treatment Outcome | 2017 |
Oral treprostinil in the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Drug Approval; Epoprostenol; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Pyrazines; Receptors, Prostaglandin; Treatment Outcome | 2017 |
What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines; Receptors, Prostaglandin; Signal Transduction | 2014 |
Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension.
Topics: Acetamides; Epoprostenol; Humans; Hypertension, Pulmonary; Prostaglandins I; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Prostaglandin | 2016 |
Selexipag: First Global Approval.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Drug Approval; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Prostaglandin | 2016 |
New paradigm for pulmonary arterial hypertension treatment.
Topics: Acetamides; Antihypertensive Agents; Clinical Trials as Topic; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Inositol 1,4,5-Trisphosphate Receptors; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyrazines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides | 2016 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Animals; Drug Approval; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines | 2016 |
A Contemporary Approach to Pulmonary Arterial Hypertension.
Topics: Acetamides; Antihypertensive Agents; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Pyrazines; Pyrimidines; Sulfonamides | 2016 |
Update on pharmacotherapy for pulmonary hypertension.
Topics: Acetamides; Antihypertensive Agents; Australia; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Pyrazines; Pyrazoles; Pyrimidines; Sulfonamides; World Health Organization | 2016 |
Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
Topics: Acetamides; Animals; Antihypertensive Agents; Drug Interactions; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Animals; Antihypertensive Agents; Delayed-Action Preparations; Drug Evaluation, Preclinical; Humans; Hypertension, Pulmonary; Pyrazines; Treatment Outcome | 2016 |
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pyrazines; Tachyphylaxis | 2016 |
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
Topics: Abatacept; Acetamides; Antibodies, Monoclonal, Humanized; Biological Products; Clinical Trials as Topic; Fibrinolytic Agents; Fibrosis; Humans; Hypertension, Pulmonary; Indoles; Inflammation; Joints; Lisuride; Lung; PubMed; Pyrazines; Pyrazoles; Pyrimidines; Scleroderma, Systemic; Skin | 2017 |
The year since the guidelines: a concise update on recent advances in pulmonary hypertension.
Topics: Acetamides; Algorithms; Guidelines as Topic; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Pyrazines; Vasodilator Agents | 2017 |
Selexipag: A Review in Pulmonary Arterial Hypertension.
Topics: Acetamides; Antihypertensive Agents; Clinical Trials as Topic; Gastrointestinal Diseases; Headache; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Pathways in pulmonary arterial hypertension: the future is here.
Topics: Acetamides; Animals; Antihypertensive Agents; Benzamides; Clinical Trials as Topic; Drugs, Investigational; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Epoprostenol; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lisuride; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Serotonin Antagonists; Sulfonamides | 2012 |
New advances in the diagnosis and treatment of POEMS syndrome.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib; Castleman Disease; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease Management; Drug Therapy, Combination; Genes, Immunoglobulin; Humans; Hypertension, Pulmonary; Lenalidomide; Melphalan; Osteosclerosis; Peripheral Blood Stem Cell Transplantation; Plasma Cells; POEMS Syndrome; Prognosis; Pyrazines; Severity of Illness Index; Symptom Assessment; Thalidomide; Transplantation, Autologous; Vascular Endothelial Growth Factor A | 2013 |
18 trial(s) available for pyrazines and Pulmonary Hypertension
| Article | Year |
|---|---|
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2022 |
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
Topics: Acetamides; Antihypertensive Agents; Comorbidity; Double-Blind Method; Heart Failure; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2022 |
Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
Topics: Acetamides; Antihypertensive Agents; Chronic Disease; Dyspnea; Humans; Hypertension, Pulmonary; Pulmonary Embolism; Pyrazines; Treatment Outcome | 2022 |
Efficacy and safety of tetramethylpyrazine phosphate on pulmonary hypertension: study protocol for a randomized controlled study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Arterial Pressure; China; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Recovery of Function; Single-Blind Method; Time Factors; Treatment Outcome; Vasodilator Agents; Young Adult | 2019 |
Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Topics: Acetamides; Adult; Aged; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol | 2017 |
Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension.
Topics: Acetamides; Acetates; Adult; Antihypertensive Agents; Bilirubin; Double-Blind Method; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Leukocyte Count; Male; Models, Biological; Natriuretic Peptide, Brain; Peptide Fragments; Pyrazines; Treatment Outcome | 2017 |
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Risk Assessment; Scleroderma, Systemic; Survival Analysis | 2017 |
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol; Time Factors; Withholding Treatment | 2018 |
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Diarrhea; Double-Blind Method; Drug Delivery Systems; Drug Therapy, Combination; Epoprostenol; Female; Headache; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Signal Transduction | 2018 |
[The effects and mechanisms of ligustrazine injection on pulmonary arterial hypertension in COPD patients].
Topics: Humans; Hypercapnia; Hypertension, Pulmonary; Pulmonary Disease, Chronic Obstructive; Pyrazines | 2016 |
[In process].
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study.
Topics: Acetamides; Adult; Antihypertensive Agents; Cardiac Surgical Procedures; Disease Progression; Double-Blind Method; Drug Monitoring; Early Medical Intervention; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Proportional Hazards Models; Pyrazines; Treatment Outcome | 2019 |
Plasma endothelin-1 and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation.
Topics: Altitude; Blood Gas Analysis; Chronic Disease; Endothelin-1; Humans; Hypertension, Pulmonary; Nitric Oxide; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pyrazines; Respiration | 2014 |
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Topics: Acetamides; Aged; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Prodrugs; Pyrazines | 2015 |
Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Adult; Aged; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Receptors, Epoprostenol; Receptors, Prostaglandin; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2012 |
[Effect of tetramethylpyrazine on endothelin, von Willebrand factor and thromboxane A2 during cardiopulmonary bypass in patients of congenital heart disease with pulmonary hypertension].
Topics: Adolescent; Adult; Calcium Channel Blockers; Cardiopulmonary Bypass; Child; Child, Preschool; Endothelins; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pyrazines; Thromboxane B2; von Willebrand Factor | 2003 |
[Clinical and experimental studies of feiyaning in treating pulmonary arterial hypertension in cor pulmonale].
Topics: Adult; Aged; Aged, 80 and over; Animals; Cardiac Output; Cross-Over Studies; Drugs, Chinese Herbal; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Heart Disease; Pyrazines; Random Allocation; Rats; Rats, Wistar; Vascular Resistance | 1994 |
[Effects in tetramethylpyrazine on TXA2 and PGI2 by cardio-pulmonary bypass in congenital heart diseases with pulmonary hypertension patients].
Topics: 6-Ketoprostaglandin F1 alpha; Adolescent; Adult; Cardiopulmonary Bypass; Child; Child, Preschool; Female; Heart Septal Defects, Atrial; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Male; Pyrazines; Thromboxane B2; Vasodilator Agents | 1998 |
51 other study(ies) available for pyrazines and Pulmonary Hypertension
| Article | Year |
|---|---|
Selexipag and the pulmonary hypertension continuum.
Topics: Acetamides; Heart Failure; Humans; Hypertension, Pulmonary; Pyrazines | 2022 |
Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
Topics: Acetamides; Adult; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Iloprost; Lupus Erythematosus, Systemic; Pulmonary Arterial Hypertension; Pyrazines; Quality of Life | 2022 |
Tetramethylpyrazine Improves Monocrotaline-Induced Pulmonary Hypertension through the ROS/iNOS/PKG-1 Axis.
Topics: Animals; Hypertension, Pulmonary; Monocrotaline; Nitric Oxide Synthase Type II; Protein Kinases; Pyrazines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2022 |
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough.
Topics: Acetamides; Humans; Hypertension, Pulmonary; Pyrazines | 2022 |
Case report: apatinib plus selexipag as a novel therapy for pulmonary tumor thrombotic microangiopathy accompanied by pulmonary hypertension associated with gastric carcinoma.
Topics: Acetamides; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Lung Neoplasms; Middle Aged; Pulmonary Artery; Pyrazines; Pyridines; Receptors, Epoprostenol; Receptors, Vascular Endothelial Growth Factor; Stomach Neoplasms; Thrombotic Microangiopathies | 2022 |
Validation of the new paediatric pulmonary hypertension risk score by CMR and speckle tracking echocardiography.
Topics: Acetamides; Child; Echocardiography; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Pyrazines; Risk Factors; Young Adult | 2022 |
Effectiveness and persistence with selexipag in pulmonary arterial hypertension in the real-life setting.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Pyrazines | 2023 |
Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Humans; Hypertension, Pulmonary; Monocrotaline; Myocytes, Smooth Muscle; Pharmaceutical Preparations; Pulmonary Artery; Pyrazines; Rats; Rats, Sprague-Dawley | 2020 |
Use of selexipag in a child with pulmonary hypertension associated with sickle cell disease.
Topics: Acetamides; Anemia, Sickle Cell; Antihypertensive Agents; Child; Female; Humans; Hypertension, Pulmonary; Prodrugs; Pulmonary Wedge Pressure; Pyrazines | 2020 |
Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Aged; Antihypertensive Agents; Blood Pressure; Drug Substitution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Pyrazines; Time Factors | 2020 |
Potential of Selexipag in Chronic Thromboembolic Pulmonary Hypertension Medical Therapy.
Topics: Acetamides; Double-Blind Method; Humans; Hypertension, Pulmonary; Japan; Pyrazines | 2020 |
A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Topics: Acetamides; Antihypertensive Agents; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines | 2021 |
Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients.
Topics: Acetamides; Adult; Antihypertensive Agents; Child; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Pyrazines | 2021 |
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Topics: Acetamides; Acetates; Animals; beta-Arrestins; Cell Proliferation; CHO Cells; Contractile Proteins; Cricetinae; Cricetulus; Cyclic AMP; Epoprostenol; Extracellular Matrix; Humans; Hypertension, Pulmonary; Iloprost; Male; Muscle Contraction; Muscle Relaxation; Pyrazines; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Epoprostenol | 2017 |
Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
Topics: Acetamides; Administration, Oral; Adult; Antihypertensive Agents; Chronic Disease; Epoprostenol; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Paraplegia; Pyrazines; Severity of Illness Index; Ventricular Dysfunction, Right | 2017 |
Single-Center Experience Using Selexipag in a Pediatric Population.
Topics: Acetamides; Adolescent; Antihypertensive Agents; Child; Epoprostenol; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pyrazines; Treatment Outcome; Walk Test; Young Adult | 2017 |
Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension.
Topics: Acetamides; Child; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
Safety concerns regarding selexipag in pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Pyrazines | 2018 |
Safety concerns regarding selexipag in pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pyrazines; Risk Evaluation and Mitigation | 2018 |
Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Drug Substitution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Male; Middle Aged; Pyrazines | 2018 |
Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
Topics: Acetamides; Decision Making; Decision Support Techniques; Humans; Hypertension, Pulmonary; Pyrazines; Quality of Life; Rare Diseases; Spain | 2018 |
Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag.
Topics: Acetamides; Administration, Oral; Cardiac Catheterization; Drug Substitution; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Pyrazines | 2019 |
The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticarcinogenic Agents; Cytoskeletal Proteins; Disease Models, Animal; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Kelch-Like ECH-Associated Protein 1; Mice; Mice, Knockout; NF-E2-Related Factor 2; Pulmonary Disease, Chronic Obstructive; Pyrazines; Tenascin; Thiones; Thiophenes | 2013 |
Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression Profiling; Hypertension, Pulmonary; Immunohistochemistry; Lung; Male; NF-kappa B; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Smad Proteins; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Vascular Remodeling | 2014 |
The effect of PS-341 on pulmonary vascular remodeling in high blood flow-induced pulmonary hypertension.
Topics: Animals; Blood Flow Velocity; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Down-Regulation; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; I-kappa B Proteins; Lung; Male; NF-KappaB Inhibitor alpha; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Signal Transduction; Transcription Factor RelA | 2014 |
Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Hypertension, Pulmonary; Induction Chemotherapy; Lenalidomide; Leukemia, Plasma Cell; Male; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide | 2014 |
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.
Topics: Acetamides; Acetates; Administration, Oral; Animals; CHO Cells; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cricetulus; Dogs; Double-Blind Method; Haplorhini; Humans; Hypertension, Pulmonary; Myocytes, Smooth Muscle; Platelet Aggregation Inhibitors; Pulmonary Artery; Pyrazines; Randomized Controlled Trials as Topic; Rats; Receptors, Epoprostenol; Structure-Activity Relationship | 2015 |
Selexipag for the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Humans; Hypertension, Pulmonary; Pyrazines | 2016 |
Selexipag (Uptravi) for pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Drug Interactions; Humans; Hypertension, Pulmonary; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Epoprostenol; Receptors, Prostaglandin; Tablets; Treatment Outcome | 2016 |
Smooth Muscle Insulin-Like Growth Factor-1 Mediates Hypoxia-Induced Pulmonary Hypertension in Neonatal Mice.
Topics: Animals; Animals, Newborn; Blood Pressure; Cell Proliferation; Chronic Disease; Gene Deletion; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Imidazoles; Insulin-Like Growth Factor I; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth; Myocytes, Smooth Muscle; Organ Specificity; Proto-Oncogene Proteins c-akt; Pulmonary Artery; Pyrazines; Receptor, IGF Type 1; RNA, Messenger; Systole; Up-Regulation; Vascular Remodeling | 2016 |
A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active fo
Topics: Acetamides; Acetates; Animals; Antihypertensive Agents; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; In Vitro Techniques; Male; Prodrugs; Pulmonary Artery; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation | 2008 |
Bortezomib alleviates experimental pulmonary arterial hypertension.
Topics: Animals; Boronic Acids; Bortezomib; Caspase 3; Cell Hypoxia; Cell Proliferation; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Heart Ventricles; Humans; Hypertension, Pulmonary; Liver; Liver Function Tests; Male; Mice; Mice, Inbred C57BL; Monocrotaline; Nitric Oxide Synthase Type III; Proteasome Inhibitors; Pulmonary Artery; Pyrazines; Rats; Rats, Sprague-Dawley | 2012 |
Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Topics: Acetamides; Acetates; Alprostadil; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Epoprostenol; Hypertension, Pulmonary; In Vitro Techniques; Male; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Receptors, Epoprostenol; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2012 |
[Pulmonary hypertension].
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Benzamides; Drug Therapy, Combination; Early Medical Intervention; Epoprostenol; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Pyrazines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides | 2012 |
[The effect of acute pulmonary alveolar hypoxia on canine plasma endothelin-1 levels].
Topics: Animals; Calcium Channel Blockers; Dogs; Endothelins; Female; Hypertension, Pulmonary; Hypoxia; Male; Pyrazines | 1994 |
[Effects of ligustrazine and nitroglycerine on acute hypoxic pulmonary hypertension in anesthetized dogs].
Topics: Acute Disease; Animals; Blood Pressure; Calcium Channel Blockers; Dogs; Female; Hypertension, Pulmonary; Hypoxia; Male; Methylene Blue; Nitroglycerin; Pyrazines; Vascular Resistance | 1994 |
Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Chronic Disease; Cyclic GMP; Dioxolanes; Dipeptides; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Imidazoles; Male; Muscle, Smooth, Vascular; Myocardium; Neprilysin; Pyrazines; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1993 |
[Changes of collagen distribution in extrapulmonary arteries of hypoxia-induced pulmonary hypertensive rat].
Topics: Altitude Sickness; Animals; Anti-Inflammatory Agents, Non-Steroidal; Collagen; Drugs, Chinese Herbal; Fibrinolytic Agents; Hypertension, Pulmonary; Male; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar | 1995 |
[Image morphological quantitative analysis of pathological changes of intra-acinar arteries in experimental pulmonary artery hypertension and outcomes of treatment].
Topics: Alkaloids; Allyl Compounds; Animals; Antihypertensive Agents; Benzylisoquinolines; Disulfides; Hypertension, Pulmonary; Image Processing, Computer-Assisted; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar | 1996 |
[Observation of relationship between function and structure of experimental pulmonary artery hypertension in rats and inhibitory effect of garlicin and other herbal medicines].
Topics: Alkaloids; Allyl Compounds; Animals; Antihypertensive Agents; Benzylisoquinolines; Blood Pressure; Disulfides; Hypertension, Pulmonary; Male; Monocrotaline; Pulmonary Artery; Pyrazines; Random Allocation; Rats; Rats, Wistar; Vasodilator Agents | 1996 |
[Effect of 764-3 and ligustrazine on collagen content of extrapulmonary arteries during chronic hypoxia].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Collagen; Drugs, Chinese Herbal; Hydroxyproline; Hypertension, Pulmonary; Hypoxia; Male; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar | 1996 |
Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Colforsin; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Hypertension, Pulmonary; Hypoxia; Imidazoles; Male; Milrinone; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pulmonary Artery; Pyrazines; Pyridones; Rats; Rats, Wistar; Vasodilation | 1998 |
ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat.
Topics: Anesthesia; Animals; Blood Gas Analysis; Blood Pressure; Endothelin Receptor Antagonists; Endothelin-1; Hematocrit; Hypertension, Pulmonary; Hypoxia; Isometric Contraction; Male; Muscle, Smooth, Vascular; Organ Size; Pulmonary Artery; Pulmonary Circulation; Pyrazines; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Sulfonamides; Ventricular Function, Right | 1999 |
Effects of ligustrazine on the pressure/flow relationship in isolated perfused rat lungs.
Topics: Animals; Arginine; Blood Flow Velocity; Blood Pressure; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Hypoxia; Male; Nitric Oxide; Pulmonary Artery; Pulmonary Circulation; Pyrazines; Rats; Rats, Inbred Strains; Vasoconstriction; Vasodilator Agents | 1991 |
[Effect of penicillamine and tetramethyl pyrazine on the hypoxic pulmonary hypertension in rats].
Topics: Animals; Female; Hypertension, Pulmonary; Hypoxia; Male; Penicillamine; Pyrazines; Rats; Rats, Inbred Strains; Vasodilator Agents | 1990 |
Effect of ligustrazine on pulmonary vascular changes induced by chronic hypoxia in rats.
Topics: Animals; Blood Pressure; Chronic Disease; Hypertension, Pulmonary; Hypoxia; Pulmonary Artery; Pyrazines; Rats; Rats, Inbred Strains; Vasodilator Agents | 1989 |
The acute effects of ligustrazini on hemodynamics and right cardiac function in pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease.
Topics: Adult; Aged; Female; Heart; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middle Aged; Pyrazines; Vasodilator Agents | 1989 |
[Inhibitory effect of ligustrazine on acute and chronic pulmonary hypertension in rats].
Topics: Animals; Calcium Channel Blockers; Hemodynamics; Hyperbaric Oxygenation; Hypertension, Pulmonary; Hypoxia; Pyrazines; Rats; Rats, Inbred Strains | 1988 |
[Dilative effect of injection of radix Angelicae, Salvia miltiorrhiza and ligustrazin on the pulmonary vessels in rats].
Topics: Animals; Blood Pressure; Drug Combinations; Drugs, Chinese Herbal; Hypertension, Pulmonary; Male; Phenanthrolines; Plant Extracts; Pulmonary Artery; Pyrazines; Rats; Rats, Inbred Strains; Salvia miltiorrhiza; Vasodilator Agents | 1988 |
[Therapeutic effects of ligustrazine on pulmonary hypertension. Report on 38 assessments with right heart catheterization and blood gas analysis].
Topics: Adult; Aged; Carbon Dioxide; Cardiac Catheterization; Female; Humans; Hypertension, Pulmonary; Injections, Intra-Arterial; Male; Middle Aged; Oxygen; Pulmonary Artery; Pyrazines | 1988 |
Effect of tetramethylpyrazine on acute and chronic hypoxic pulmonary hypertension of the rat.
Topics: Animals; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Male; Pyrazines; Rats; Rats, Inbred Strains; Vasodilator Agents | 1986 |